Apollo Health Ventures

Auron Therapeutics, Inc. is a biotechnology company based in Wellesley, Massachusetts, founded in 2018. The company is dedicated to developing innovative therapies for cancer, aiming to shift the traditional focus from merely killing cancer cells to transforming malignant cells into normal, functioning cells through a process known as differentiation therapy. This approach seeks to reactivate the body's innate cellular programs, promoting tumor cell maturation and the restoration of normal tissue. Auron Therapeutics leverages advanced platforms that integrate large genomic datasets and utilize high-throughput flow cytometry to efficiently identify and validate potential drug targets in primary human patient samples. Through its research, the company aims to address significant unmet medical needs in oncology, ultimately striving to deliver life-saving and transformative treatments for cancer patients.

Developer of therapeutic medicines intended to treat age-related diseases and improve healthy longevity. The company researches FOXO proteins that regulate multiple genes involved in processes like stress resistance, and metabolism and develops novel modulators of a central stress response pathway to modulate aging through genetics, enabling patients to extend the years of healthy living.

Booster Therapeutics is a biotechnology company focused on developing innovative medicines aimed at addressing aging-related diseases. The company specializes in regulating cellular homeostasis, which involves restoring balance within cells to eliminate toxic accumulations. By targeting the cellular systems responsible for maintaining cellular health, Booster Therapeutics aims to create drug modalities that can prevent and treat various diseases associated with aging.

Aeovian Pharmaceuticals is a biopharmaceutical company based in the San Francisco Bay Area, specializing in the development and commercialization of innovative therapeutics targeting age-related and rare diseases. Founded in 2012, the company focuses on creating compounds that inhibit the mTORC1 and mTORC2 pathways, which are critical in addressing the underlying causes of disease initiation and progression, including oxidative, cellular, and environmental stress. By targeting these molecular pathways, Aeovian Pharmaceuticals aims to provide effective treatment options for patients and healthcare providers. The company was previously known as Delos Pharmaceuticals, reflecting its commitment to advancing therapeutic solutions in the biopharmaceutical sector.

Cleara Biotech B.V. is a biotechnology company based in Utrecht, the Netherlands, focused on developing innovative therapeutics to selectively eliminate senescent and senescent-like cancer cells. The company specializes in creating FOXO4-based anti-senescence drugs aimed at addressing chemotoxicity and combating therapy-resistant cancer cells. Cleara Biotech's research targets a crucial aspect of cancer treatment by aiming to enhance the effectiveness of therapies and improve patient outcomes through the targeted removal of problematic cell populations.

Auron Therapeutics, Inc. is a biotechnology company based in Wellesley, Massachusetts, founded in 2018. The company is dedicated to developing innovative therapies for cancer, aiming to shift the traditional focus from merely killing cancer cells to transforming malignant cells into normal, functioning cells through a process known as differentiation therapy. This approach seeks to reactivate the body's innate cellular programs, promoting tumor cell maturation and the restoration of normal tissue. Auron Therapeutics leverages advanced platforms that integrate large genomic datasets and utilize high-throughput flow cytometry to efficiently identify and validate potential drug targets in primary human patient samples. Through its research, the company aims to address significant unmet medical needs in oncology, ultimately striving to deliver life-saving and transformative treatments for cancer patients.

HAYA Therapeutics is a company focused on developing RNA-based therapeutics aimed at treating heart failure and other fibrotic diseases. The company specializes in biopharmaceutical therapies that target specific regulators of fibrosis, particularly long noncoding RNA, which plays a critical role in myocardial fibrosis. By honing in on heart-specific mechanisms, HAYA Therapeutics seeks to enhance the efficacy and safety of treatments for heart-related illnesses and other serious conditions associated with aging, including cancer. Through its innovative approach, the company aims to improve patient outcomes in the management of heart failure and related health challenges.

Bloom Science, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, that specializes in developing neuroprotective therapies leveraging the microbiome to treat epilepsy and other neurological disorders. Founded in 2017, the company employs its proprietary IrisRx™ platform to explore innovative treatments that target the Gut-Brain Axis, aiming to create therapeutics with enhanced safety profiles. Bloom Science's approach focuses on harnessing gut commensal microbes and integrating insights from synthetic biology to develop multi-functional therapeutics. The company is advancing a robust pipeline of programs addressing complex conditions such as Dravet syndrome, various rare epilepsies, Amyotrophic Lateral Sclerosis (ALS), and other neurodegenerative and cognitive disorders, with the goal of delivering transformative solutions for patients facing serious, life-altering illnesses.

Ochre Bio Ltd is a biotechnology company focused on developing genomic medicines specifically for transplanted livers and the treatment of fatty liver conditions. Founded in 2019 and based in Headington, United Kingdom, the company employs advanced genomic techniques to identify and inhibit overactive genes associated with liver diseases. This approach includes testing therapies in discarded donor livers that are maintained outside the body, ensuring that potential treatments can be evaluated in a relevant biological context. With over 15 years of expertise in liver genomics research, Ochre Bio aims to create a pipeline of innovative medicines that address liver and liver-mediated conditions, ultimately enhancing the availability of healthy livers for transplantation and reducing complications associated with cirrhosis. The company operates within Oxford's biotechnology innovation hub, leveraging its scientific foundation to advance therapeutic solutions in the field of liver health.

HAYA Therapeutics is a company focused on developing RNA-based therapeutics aimed at treating heart failure and other fibrotic diseases. The company specializes in biopharmaceutical therapies that target specific regulators of fibrosis, particularly long noncoding RNA, which plays a critical role in myocardial fibrosis. By honing in on heart-specific mechanisms, HAYA Therapeutics seeks to enhance the efficacy and safety of treatments for heart-related illnesses and other serious conditions associated with aging, including cancer. Through its innovative approach, the company aims to improve patient outcomes in the management of heart failure and related health challenges.

HAYA Therapeutics is a company focused on developing RNA-based therapeutics aimed at treating heart failure and other fibrotic diseases. The company specializes in biopharmaceutical therapies that target specific regulators of fibrosis, particularly long noncoding RNA, which plays a critical role in myocardial fibrosis. By honing in on heart-specific mechanisms, HAYA Therapeutics seeks to enhance the efficacy and safety of treatments for heart-related illnesses and other serious conditions associated with aging, including cancer. Through its innovative approach, the company aims to improve patient outcomes in the management of heart failure and related health challenges.

Samsara Therapeutics, founded in 2018 with operations across Europe and San Diego, is a biopharmaceutical company dedicated to discovering and developing therapeutics for age-related diseases and unmet medical needs. Its proprietary platform focuses on identifying and validating compounds that extend healthy lifespan by targeting fundamental aging processes such as proteostasis and autophagy. The company aims to create novel treatments for rare genetic and neurodegenerative diseases through its pipeline, which involves compound identification, chemical optimization, and in vivo validation across various species.

Aeovian Pharmaceuticals is a biopharmaceutical company based in the San Francisco Bay Area, specializing in the development and commercialization of innovative therapeutics targeting age-related and rare diseases. Founded in 2012, the company focuses on creating compounds that inhibit the mTORC1 and mTORC2 pathways, which are critical in addressing the underlying causes of disease initiation and progression, including oxidative, cellular, and environmental stress. By targeting these molecular pathways, Aeovian Pharmaceuticals aims to provide effective treatment options for patients and healthcare providers. The company was previously known as Delos Pharmaceuticals, reflecting its commitment to advancing therapeutic solutions in the biopharmaceutical sector.

Samsara Therapeutics, founded in 2018 with operations across Europe and San Diego, is a biopharmaceutical company dedicated to discovering and developing therapeutics for age-related diseases and unmet medical needs. Its proprietary platform focuses on identifying and validating compounds that extend healthy lifespan by targeting fundamental aging processes such as proteostasis and autophagy. The company aims to create novel treatments for rare genetic and neurodegenerative diseases through its pipeline, which involves compound identification, chemical optimization, and in vivo validation across various species.

Cleara Biotech B.V. is a biotechnology company based in Utrecht, the Netherlands, focused on developing innovative therapeutics to selectively eliminate senescent and senescent-like cancer cells. The company specializes in creating FOXO4-based anti-senescence drugs aimed at addressing chemotoxicity and combating therapy-resistant cancer cells. Cleara Biotech's research targets a crucial aspect of cancer treatment by aiming to enhance the effectiveness of therapies and improve patient outcomes through the targeted removal of problematic cell populations.

Aeovian Pharmaceuticals is a biopharmaceutical company based in the San Francisco Bay Area, specializing in the development and commercialization of innovative therapeutics targeting age-related and rare diseases. Founded in 2012, the company focuses on creating compounds that inhibit the mTORC1 and mTORC2 pathways, which are critical in addressing the underlying causes of disease initiation and progression, including oxidative, cellular, and environmental stress. By targeting these molecular pathways, Aeovian Pharmaceuticals aims to provide effective treatment options for patients and healthcare providers. The company was previously known as Delos Pharmaceuticals, reflecting its commitment to advancing therapeutic solutions in the biopharmaceutical sector.

HAYA Therapeutics is a company focused on developing RNA-based therapeutics aimed at treating heart failure and other fibrotic diseases. The company specializes in biopharmaceutical therapies that target specific regulators of fibrosis, particularly long noncoding RNA, which plays a critical role in myocardial fibrosis. By honing in on heart-specific mechanisms, HAYA Therapeutics seeks to enhance the efficacy and safety of treatments for heart-related illnesses and other serious conditions associated with aging, including cancer. Through its innovative approach, the company aims to improve patient outcomes in the management of heart failure and related health challenges.

Therini Bio is a biotechnology company focused on developing fibrin-targeting therapies aimed at treating inflammatory neurological and retinal diseases. The company leverages groundbreaking research from the Akassoglou lab at Gladstone/UCSF, which identifies fibrin as a crucial factor in driving chronic innate immune activation associated with various diseases. By creating therapeutics that address neuroinflammation and vascular dysfunction, Therini Bio aims to provide potential treatments for conditions such as multiple sclerosis, thereby enhancing the quality of life for patients facing these challenging health issues.